Griffin Health Nuclear Medicine, Molecular Imaging and Theranostics Department has expanded its capabilities for more accurate and timely diagnoses of Parkinson’s disease.
Griffin is now offering DaTscan® (Ioflupane I 123), an innovative diagnostic molecular imaging tool used to evaluate dopamine transporter availability in the brain. With expansion of services to include this type of neuroimaging, Griffin Health is enhancing its ability to assist neurologists, primary care physicians and other specialists in differentiating between Parkinson’s disease and other movement disorders, supporting more accurate and timely diagnoses.
DaTscan imaging involves injecting a small amount of the radiopharmaceutical (a specialized drug that has a radioactive component) into the bloodstream, followed by a single-photon emission computed tomography (SPECT) scan to capture detailed images of the brain. This procedure is non-invasive, safe, and typically takes less than an hour to complete.
“The addition of DaTscan provides a significant advancement, improving the accuracy and timeliness of diagnoses for patients with Parkinsonian syndromes,” said Griffin Health Vice President of Diagnostic and Cancer Services Christine Cooper, MS, CNMT, RT(N), RSO, FACHE, FAB. “With early and accurate diagnosis, patients can receive appropriate treatment more quickly, which can have a positive impact on their long-term health and quality of life.”
Griffin Health is now accepting referrals for DaTscan. Referring providers can contact the Griffin Nuclear Medicine Department at 203-732-7271 for more information and orders can be faxed to Central Scheduling at 203-732-1559. For more information, visit www.griffinhealth.org/datscan.